Clinical nutrition ESPEN · 2026
Get a grip! - Baseline handgrip strength and sarcopenia as predictors of survival in patients with head and neck squamous cell carcinoma.
СтатьяНаблюдательное исследованиеНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Orell Helena, Pohju Anne, Ravasco Paula, Schwab Ursula, Osterlund Pia, Mäkitie Antti A
Аннотация
BACKGROUND: Low handgrip strength (HGS) and sarcopenia are common in patients with head and neck squamous cell carcinoma (HNSCC). This study aimed to explore associations between baseline HGS, fat-free mass index (FFMI), nutritional indices, and survival.
METHODS: This was a prospective observational sub-study of a randomized nutritional intervention trial, including 50 male patients with HNSCC undergoing curative-intent treatment (surgery and/or (chemo)radiotherapy). Sarcopenia was defined as low HGS (<27 kg) and FFMI (<17 kg/m2). Chi-square, Kaplan-Meier, and Cox analyses were used.
RESULTS: Low HGS was observed in 16%, low FFMI in 46%, and sarcopenia in 12%. Patients with low HGS had lower body weight, BMI, and FFMI, alongside more malnutrition, elevated CRP, and heavy smoking. Low HGS and sarcopenia were associated with shorter overall survival (HR 3.7, [95% CI 1.5-9.1] and 5.5, [2.2-14.5], respectively); FFMI was not. Adjustment removed significance. Findings should be interpreted cautiously due to the small, all-male cohort size.
CONCLUSION: In this small exploratory cohort HGS may serve as a simple screening surrogate for sarcopenia and survival.
CLINICAL TRIAL REGISTRATION: www.
CLINICALTRIALS: gov, identifier NCT02159508.
METHODS: This was a prospective observational sub-study of a randomized nutritional intervention trial, including 50 male patients with HNSCC undergoing curative-intent treatment (surgery and/or (chemo)radiotherapy). Sarcopenia was defined as low HGS (<27 kg) and FFMI (<17 kg/m2). Chi-square, Kaplan-Meier, and Cox analyses were used.
RESULTS: Low HGS was observed in 16%, low FFMI in 46%, and sarcopenia in 12%. Patients with low HGS had lower body weight, BMI, and FFMI, alongside more malnutrition, elevated CRP, and heavy smoking. Low HGS and sarcopenia were associated with shorter overall survival (HR 3.7, [95% CI 1.5-9.1] and 5.5, [2.2-14.5], respectively); FFMI was not. Adjustment removed significance. Findings should be interpreted cautiously due to the small, all-male cohort size.
CONCLUSION: In this small exploratory cohort HGS may serve as a simple screening surrogate for sarcopenia and survival.
CLINICAL TRIAL REGISTRATION: www.
CLINICALTRIALS: gov, identifier NCT02159508.